Literature DB >> 29992462

Controversies in the management of stage I seminoma: adjuvant carboplatin revisited.

J Aparicio1, J Terrasa2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29992462     DOI： 10.1007/s12094-018-1917-1

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  9 in total

1.  Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214).

Authors:  R Timothy D Oliver; Graham M Mead; Gordon J S Rustin; Johnathan K Joffe; Nina Aass; Robert Coleman; Rhian Gabe; Philip Pollock; Sally P Stenning
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

2.  Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA).

Authors:  T Tandstad; O Ståhl; O Dahl; H S Haugnes; U Håkansson; Å Karlsdottir; A Kjellman; C W Langberg; A Laurell; J Oldenburg; A Solberg; K Söderström; U Stierner; E Cavallin-Ståhl; R Wahlqvist; N Wall; G Cohn-Cedermark
Journal:  Ann Oncol       Date:  2016-04-06       Impact factor: 32.976

3.  Surveillance versus adjuvant radiotherapy for patients with high-risk stage I seminoma.

Authors:  Mette S Mortensen; Mikkel Bandak; Maria G G Kier; Jakob Lauritsen; Mads Agerbaek; Niels V Holm; Hans von der Maase; Gedske Daugaard
Journal:  Cancer       Date:  2016-11-28       Impact factor: 6.860

4.  Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in-Time to Start Backing Out.

Authors:  Rune A W van de Wetering; Stefan Sleijfer; Darren R Feldman; Samuel A Funt; George J Bosl; Ronald de Wit
Journal:  J Clin Oncol       Date:  2018-02-01       Impact factor: 44.544

5.  Mortality after cure of testicular seminoma.

Authors:  Gunar K Zagars; Matthew T Ballo; Andrew K Lee; Sara S Strom
Journal:  J Clin Oncol       Date:  2004-01-15       Impact factor: 44.544

6.  Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG).

Authors:  J Aparicio; P Maroto; X García del Muro; A Sánchez-Muñoz; J Gumà; M Margelí; A Sáenz; N Sagastibelza; D Castellano; J A Arranz; D Hervás; R Bastús; A Fernández-Aramburo; J Sastre; J Terrasa; M López-Brea; J Dorca; D Almenar; J Carles; A Hernández; J R Germà
Journal:  Ann Oncol       Date:  2014-09-10       Impact factor: 32.976

Review 7.  Non-risk-adapted Surveillance for Stage I Testicular Cancer: Critical Review and Summary.

Authors:  Phillip Martin Pierorazio; Peter Albers; Peter C Black; Torgrim Tandstad; Axel Heidenreich; Nicola Nicolai; Craig Nichols
Journal:  Eur Urol       Date:  2018-01-12       Impact factor: 20.096

8.  Carboplatin dose based on actual renal function: no excess of acute haematotoxicity in adjuvant treatment in seminoma stage I.

Authors:  Martin Fehr; Angela Fischer Maranta; Hermann Reichegger; Silke Gillessen; Richard Cathomas
Journal:  ESMO Open       Date:  2018-03-08

9.  Testicular seminoma clinical stage 1: treatment outcome on a routine care level.

Authors:  Klaus-Peter Dieckmann; Inken Dralle-Filiz; Cord Matthies; Julia Heinzelbecker; Jens Bedke; Jörg Ellinger; Petra Anheuser; Rainer Souchon; Uwe Pichlmeier
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-26       Impact factor: 4.553
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.